Stock listing
Lang & Schwarz:935051 Proteome Sciences plc Aktie
German listing (Lang & Schwarz) of Proteome Sciences plc · home listing LSE:PRM
Follow Proteome Sciences plc into a list and get an email when it puts out news.
Home listing price · LSE:PRM
0.97p GBX (pence) -0.20 (-17.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, LSE:PRM
- Day range
- 0.97p – 1.30p GBX (pence)Nov 20, 2026
- Volume
- 827,508 sharesNov 20, 2026
- Market cap
- £3.40M GBPAt the close on Nov 20, 2026 · price × 350.7M shares outstanding
- 52-week range
- 0.97p – 4.40p GBX (pence)Lowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- £3,882 GBPMedian day 58,529 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| LSE:PRM · Home | 0.97p GBX (pence) | -0.20 (-17.1%) | 827,508 | 1.00p | 1.30p | 0.97p | 1.17p | Close on Nov 20, 2026 |
| Frankfurt:PI2 | €0.0040 EUR | +0.0010 (+33.3%) | — | €0.0040 | €0.0040 | €0.0040 | €0.0030 | Close on Nov 17, 2026 |
| Munich:PI2 | €0.0005 EUR | -0.0145 (-96.7%) | — | €0.0140 | €0.0140 | €0.0005 | €0.0150 | Close on Nov 20, 2026 |
| OTC:PMSNF | $0.011 USD | +0.001 (+11.0%) | 9,650 | $0.021 | $0.021 | $0.011 | $0.010 | Close on Nov 17, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · LSE:PRM · GBX (pence), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 0.97p | -0.20 | -17.1% | 1.00p | 1.30p | 0.97p | 827,508 | |
| 1.17p | -0.06 | -4.9% | 1.05p | 1.33p | 1.01p | 3,622 | |
| 1.23p | -0.15 | -10.9% | 1.01p | 1.23p | 1.01p | 3,608 | |
| 1.38p | -0.02 | -1.4% | 1.10p | 1.38p | 1.04p | 499,557 | |
| 1.40p | +0.04 | +2.9% | 1.16p | 1.40p | 1.16p | 96,165 | |
| 1.36p | +0.065 | +5.0% | 1.61p | 1.61p | 1.36p | 6,211 | |
| 1.295p | -0.055 | -4.1% | 1.68p | 1.68p | 1.10p | 194,817 | |
| 1.35p | -0.105 | -7.2% | 1.20p | 1.69p | 1.20p | 139,611 | |
| 1.455p | +0.005 | +0.3% | 1.68p | 1.69p | 1.21p | 5,659 | |
| 1.45p | +0.07 | +5.1% | 1.69p | 1.69p | 1.20p | 108,266 | |
| 1.38p | -0.075 | -5.2% | 1.55p | 1.55p | 1.38p | 137 | |
| 1.455p | +0.005 | +0.3% | 1.21p | 1.68p | 1.21p | 9,629 | |
| 1.45p | +0.105 | +7.8% | 1.21p | 1.68p | 1.21p | 31,933 | |
| 1.345p | -0.11 | -7.6% | 1.21p | 1.68p | 1.21p | 1,545,372 | |
| 1.455p | 0.00 | 0.0% | 1.68p | 1.68p | 1.244p | 50,060 | |
| 1.455p | -0.005 | -0.3% | 1.69p | 1.69p | 1.455p | 64 | |
| 1.46p | +0.06 | +4.3% | 1.22p | 1.69p | 1.22p | 270,196 | |
| 1.40p | -0.05 | -3.4% | 1.21p | 1.69p | 1.21p | 1,338 | |
| 1.45p | 0.00 | 0.0% | 1.68p | 1.68p | 1.45p | 80,973 | |
| 1.45p | +0.105 | +7.8% | 1.21p | 1.68p | 1.21p | 9,133 | |
| 1.345p | 0.00 | 0.0% | 1.21p | 1.49p | 1.21p | 20,585 | |
| 1.345p | 0.00 | 0.0% | 1.48p | 1.48p | 1.345p | 68 | |
| 1.345p | -0.005 | -0.4% | 1.21p | 1.50p | 1.21p | 251,201 | |
| 1.35p | -0.105 | -7.2% | 1.70p | 1.70p | 1.35p | 977 | |
| 1.455p | +0.105 | +7.8% | 1.21p | 1.70p | 1.21p | 217,021 | |
| 1.35p | 0.00 | 0.0% | 1.21p | 1.49p | 1.21p | 51,589 | |
| 1.35p | -0.005 | -0.4% | 1.49p | 1.49p | 1.21p | 63,999 | |
| 1.355p | -0.005 | -0.4% | 1.21p | 1.50p | 1.21p | 57,906 | |
| 1.36p | 0.00 | 0.0% | 1.49p | 1.50p | 1.21p | 115,426 | |
| 1.36p | +0.005 | +0.4% | 1.225p | 1.36p | 1.225p | 460 | |
| 1.355p | 0.00 | 0.0% | 1.69p | 1.69p | 1.27p | 210,336 | |
| 1.355p | -0.065 | -4.6% | 1.60p | 1.60p | 1.21p | 1,135 | |
| 1.42p | -0.035 | -2.4% | 1.64p | 1.70p | 1.20p | 10,410 | |
| 1.455p | +0.055 | +3.9% | 1.21p | 1.455p | 1.21p | 4,527 | |
| 1.40p | -0.05 | -3.4% | 1.501p | 1.60p | 1.21p | 9,103 | |
| 1.45p | 0.00 | 0.0% | 1.69p | 1.69p | 1.45p | 4,730 | |
| 1.45p | -0.005 | -0.3% | 1.69p | 1.69p | 1.21p | 59,152 | |
| 1.455p | 0.00 | 0.0% | 1.20p | 1.69p | 1.20p | 3,770 | |
| 1.455p | +0.055 | +3.9% | 1.69p | 1.69p | 1.20p | 537 | |
| 1.40p | +0.075 | +5.7% | 1.20p | 1.69p | 1.20p | 107,499 | |
| 1.325p | -0.125 | -8.6% | 1.45p | 1.45p | 1.325p | 115,426 | |
| 1.45p | -0.045 | -3.0% | 1.69p | 1.69p | 1.45p | 59 | |
| 1.495p | +0.015 | +1.0% | 1.69p | 1.69p | 1.27p | 63,616 | |
| 1.48p | 0.00 | 0.0% | 1.51p | 1.69p | 1.48p | 2,186 | |
| 1.48p | 0.00 | 0.0% | 1.26p | 1.69p | 1.26p | 227,418 | |
| 1.48p | +0.08 | +5.7% | 1.27p | 1.69p | 1.27p | 74,178 | |
| 1.40p | -0.05 | -3.4% | 1.60p | 1.70p | 1.209p | 726,156 | |
| 1.45p | 0.00 | 0.0% | 1.69p | 1.69p | 1.259p | 5,134,541 | |
| 1.45p | +0.05 | +3.6% | 1.59p | 1.60p | 1.11p | 869,738 | |
| 1.40p | 0.00 | 0.0% | 1.21p | 1.59p | 1.20p | 28,411 | |
| 1.40p | 0.00 | 0.0% | 1.21p | 1.60p | 1.21p | 33,588 | |
| 1.40p | 0.00 | 0.0% | 1.60p | 1.60p | 1.20p | 726 | |
| 1.40p | 0.00 | 0.0% | 1.60p | 1.60p | 1.21p | 232 | |
| 1.40p | 0.00 | 0.0% | 1.21p | 1.59p | 1.21p | 2,633 | |
| 1.40p | 0.00 | 0.0% | 1.60p | 1.60p | 1.40p | 4,629 | |
| 1.40p | -0.05 | -3.4% | 1.21p | 1.60p | 1.21p | 4,662 | |
| 1.45p | +0.05 | +3.6% | 1.60p | 1.60p | 1.45p | 392,957 | |
| 1.40p | -0.005 | -0.4% | 1.58p | 1.59p | 1.21p | 291,547 | |
| 1.405p | -0.145 | -9.4% | 1.31p | 1.79p | 1.31p | 457,661 | |
| 1.55p | -0.025 | -1.6% | 1.50p | 1.85p | 1.31p | 603,747 | |
| 1.575p | -0.005 | -0.3% | 1.40p | 1.86p | 1.40p | 180,100 | |
| 1.58p | -0.005 | -0.3% | 1.31p | 1.87p | 1.31p | 1,171,232 | |
| 1.585p | +0.035 | +2.3% | 1.78p | 1.78p | 1.417p | 327,792 | |
| 1.55p | -0.045 | -2.8% | 1.456p | 1.80p | 1.436p | 1,077,611 | |
| 1.595p | -0.105 | -6.2% | 1.60p | 1.99p | 1.425p | 226,719 | |
| 1.70p | -0.095 | -5.3% | 1.60p | 1.99p | 1.60p | 718,017 |
Splits
1 split · LSE:PRM · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 37-for-35 | Split |
- Ticker
- Lang & Schwarz:935051
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Sep 16, 2026
Appointment of Non-Executive Director
Latest news
Appointment of Non-Executive Director
Sep 16, 2026
Closed 1.45p (0.0%) on Sep 16, 2026
Further GCLP Chemoproteomics contract secured
Sep 15, 2026
Closed 1.45p (+3.6%) on Sep 15, 2026
Target engagement/chemoproteomics contract
Jun 22, 2026
Closed 1.50p (-0.7%) on Jun 22, 2026
Annual General Meeting Statement
May 14, 2026
Closed 1.85p (0.0%) on May 14, 2026
Final results for the year ended 31 December 2025
Apr 15, 2026
Closed 1.50p (-4.8%) on Apr 15, 2026
Holding(s) in Company
Feb 4, 2026
Closed 1.80p (+0.8%) on Feb 4, 2026
Result of Oversubscribed Retail Offer
Jan 28, 2026
Closed 1.91p (-2.3%) on Jan 28, 2026
Retail Offer to raise up to £60,000
Jan 26, 2026
Closed 1.91p (-41.0%) on Jan 26, 2026
Two Further Substantial Contracts for PRM
Jan 6, 2026
Closed 3.41p (+26.3%) on Jan 6, 2026
Substantial contract for Proteome Sciences
Dec 8, 2025
Closed 2.36p (-9.2%) on Dec 8, 2025
Proteome Sciences plc on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 11 in the last 12 months · 217 in all · newest Sep 16, 2026 · oldest 1999
- Calls
- 7 calls with a replay · 7 with a transcript · latest Apr 11, 2025
- Decks
- 1 deck · latest Sep 5, 2006
Where Proteome Sciences plc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| LSE:PRM · Home listing | LSE | United Kingdom | GBX |
| LS Exchange:935051 | LS Exchange | Germany | EUR |
| Lang & Schwarz:935051 · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:PI2 | Frankfurt | Germany | EUR |
| Stuttgart:PI2 | Stuttgart | Germany | EUR |
| Turquoise:PRML | Turquoise | United Kingdom | GBX |
| AQUIS:PRM.GB | AQUIS | United Kingdom | GBX |
| Munich:PI2 | Munich | Germany | EUR |
| OTC:PMSNF | OTC | United States | USD |
Valuation
EV/sales 4.9× against a median of 0.6×: 7th lowest of 10 Diagnostics & research services companies shown. Statements: Year to Dec 31, 2025 · balance Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- £18.25M GBP
- P/E
- Loss
- EV/sales
- 4.9×
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- −26.8%
- Operating margin
- −71.0%
- Net margin
- −81.5%
- Debt to equity
- Negative equity
- Beta
- No index for this market yet
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Proteome Sciences plc · LSE:PRM | US$4.45M | US$23.87M | n/a | 4.9× | n/a | n/a | −81.5% | n/a | n/a |
| VivoSim Labs, Inc. · NASDAQ:VIVS | US$5.29M | −US$2.76M | n/a | −20.5× | n/a | 0.7× | n/a | 0.1× | 1.91 |
| Biomerica, Inc. · NASDAQ:BMRA | US$4.97M | US$2.23M | n/a | 0.5× | n/a | 1.4× | −115.5% | 0.0× | 0.71 |
| VolitionRx Limited · AMEX:VNRX | US$4.87M | US$9.19M | n/a | 2.7× | n/a | n/a | −698.5% | n/a | 1.52 |
| Boule Diagnostics AB · OMXSTO:BOUL | US$4.84M | US$24.70M | n/a | 0.6× | n/a | 0.3× | −4.0% | 1.3× | n/a |
| BioInfra Co.,Ltd. · KRX:199730 | US$4.75M | −US$509,202 | n/a | −0.0× | n/a | 0.5× | −32.3% | 0.0× | n/a |
| Cardio Diagnostics Holdings Inc. · NASDAQ:CDIO | US$4.74M | US$4.74M | n/a | 312× | n/a | 0.8× | n/a | 0.0× | 2.07 |
| Niki BioSolutions, Inc. · NASDAQ:NIKI | US$4.61M | US$4.60M | n/a | n/a | n/a | 0.2× | n/a | 0.1× | 1.46 |
| Cambridge Nutritional Sciences PLC · LSE:CNSL | US$4.51M | US$1.23M | n/a | 0.1× | n/a | 0.6× | −83.5% | 0.0× | n/a |
| Immunovia AB · OMXSTO:IMMNOV | US$3.95M | US$2.31M | n/a | 12.1× | n/a | 6.1× | n/a | 0.4× | n/a |
| SDS Optic Spolka Akcyjna · NEWCONNECT:SDS | US$3.81M | US$3.57M | n/a | 13.7× | n/a | 11.8× | −269.4% | 0.0× | n/a |
| Median of the others | US$4.74M | US$2.94M | 0.6× | 0.7× | −99.5% | 0.0× | 1.52 |
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher Pearce | Executive Chairman |
| Richard Dennis | Chief Commercial Officer and Executive Director |
Board
| Director | Role |
|---|---|
| Christopher Pearce | Executive Chairman |
| Helen Spice | Director |
| Ian Pike | Board Member |
| Martin Diggle | Board Member |
| Richard Dennis | Chief Commercial Officer and Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Proteome Sciences (LSE:PRM) — Final Results for the Year Ending 31st December 2024 | Fri, Apr 11, 2025 · 5:30 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Annual General Meeting | Thu, May 16, 2024 · 7:00 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Half Year Results | Tue, Sep 19, 2023 · 5:00 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Annual General Meeting | Wed, May 17, 2023 · 7:00 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Interim Results | Thu, Aug 18, 2022 · 5:30 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Annual General Meeting | Mon, May 16, 2022 · 7:00 AM ET | Replay |
| Proteome Sciences (LSE:PRM) — Full Year Results for the Year Ended 31 December 2020 | Thu, Apr 08, 2021 · 5:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q2 2025 | Sep 11, 2025 · Before open | 0.0% |
| Quarter to Mar 31, 2025 | Apr 18, 2025 | +3.3% |
| Q1 2023 | Apr 4, 2023 · Before open | +8.3% |
| Q2 2022 | Aug 4, 2022 | +0.7% |
| Q4 2021 | Mar 31, 2022 | −0.8% |
| Q2 2021 | Jul 29, 2021 | −2.6% |
| Q1 2021 | Apr 12, 2021 | +0.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| 7th Siena Meeting From Genome to Proteome: Back to the Future (September 2006) | Conference | 27 slides | Sep 5, 2006 |
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Retail Offer Shares (new ordinary shares) Closed: £132,000 raised · GBX 1.75 a share · SP Angel Corporate Finance LLP Dealers: SP Angel Corporate Finance LLP Use of proceeds: TMT tag plexing increase, new DXT isotopic plex tags and licence, Solvent Shift workflows, San Diego staff and MS capacity, working capital | Jan 28, 2026 | US$181,907 |
| Private placement of new ordinary shares Announced: GBX 1.75 a share | Jan 26, 2026 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in GBP
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.76M | 4.89M | 5.03M | 7.78M | 5.12M | 4.71M | 4.63M | 3.05M | 3.38M | 2.74M |
| Cost of revenue | 4.76M | 5.05M | 3.87M | 3.01M | 2.17M | 2.17M | 1.70M | 1.18M | 1.18M | 1.20M |
| Gross profit | -1.01M | -167.0K | 1.16M | 4.77M | 2.96M | 2.54M | 2.93M | 1.87M | 2.20M | 1.55M |
| Research and development | 606.0K | 637.0K | 376.0K | 287.0K | 202.0K | 355.0K | 441.0K | 441.0K | 1.07M | |
| Selling, general and administrative | 2.58M | 3.02M | 3.27M | 2.64M | 2.33M | 2.04M | 2.65M | 3.24M | 4.01M | 4.24M |
| Operating income | -2.67M | -2.27M | -1.47M | 1.49M | 512.0K | 526.0K | 279.0K | -1.37M | -1.80M | -2.67M |
| Depreciation and amortization | 926.0K | 837.0K | 484.0K | 284.0K | 213.0K | 165.0K | 89.0K | 229.0K | 332.0K | 553.0K |
| EBITDA | -1.74M | -1.44M | -986.0K | 1.77M | 725.0K | 691.0K | 368.0K | -1.14M | -1.46M | -2.12M |
| Interest expense | 925.0K | 895.0K | 797.0K | 473.0K | 294.0K | 304.0K | 335.0K | 289.0K | 246.0K | 257.0K |
| Income before tax | -3.59M | -3.25M | -2.42M | 1.25M | 118.0K | 245.0K | -36.0K | -1.66M | -2.05M | -2.94M |
| Income tax | -530.0K | 158.0K | 25.0K | -70.0K | 46.0K | -50.0K | -185.0K | -346.0K | 444.0K | -663.0K |
| Net income | -3.06M | -3.41M | -2.44M | 1.32M | 72.0K | 295.0K | 149.0K | -1.31M | -2.50M | -2.28M |
| Earnings per share, basic | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | -0.01 | -0.01 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 781.0K | 1.13M | 2.03M | 252.9B | 240.3B | 193.7B | 153.4B | 180.0B | 175.3B | 106.9B |
| Receivables | 754.0K | 509.0K | 1.05M | 1.57M | 927.0K | 1.13M | 1.67M | 590.0K | 1.06M | 1.34M |
| Inventory | 537.0K | 732.0K | 837.0K | 901.0K | 1.09M | 878.0K | 871.0K | 1.15M | 946.0K | 600.0K |
| Current assets | 2.07M | 2.59M | 4.16M | 252.9B | 240.3B | 193.7B | 153.4B | 180.0B | 175.3B | 106.9B |
| Property, plant and equipment | 1.27M | 542.0K | 656.0K | 56.0K | 281.0K | 592.0K | ||||
| Goodwill | 4.22M | 4.22M | 4.22M | 3.91B | 3.89B | 3.89B | 3.90B | 3.91B | 3.90B | 3.92B |
| Total assets | 8.26M | 9.21M | 11.5M | 1.51T | 1.38T | 1.35T | 1.14T | 1.13T | 1.13T | 1.21T |
| Accounts payable | 1.43M | 639.0K | 449.0K | 672.0K | 375.0K | 519.0K | 514.0K | 372.0K | 413.0K | 28.0K |
| Current liabilities | 16.6M | 14.0M | 12.5M | 4.62B | 4.17B | 3.68B | 3.47B | 3.88B | 3.95B | 9.36M |
| Long-term debt | 0 | 250.0K | 0 | 166.0K | ||||||
| Total debt | 15.8M | 14.5M | 13.5M | 139.9B | 138.6B | 120.9B | 128.0B | 127.2B | 114.3B | 119.1B |
| Total liabilities | 17.8M | 15.7M | 14.5M | 1.44T | 1.31T | 1.28T | 1.07T | 1.07T | 1.07T | 119.1B |
| Shareholders' equity | -9.53M | -6.52M | -3.07M | 68.3B | 69.1B | 65.8B | 64.4B | 62.6B | 63.9B | 64.9B |
| Shares outstanding | 295.2M | 295.2M | 295.2M | 309.0M | 301.9M | 295.2M | 295.2M | 295.2M | 295.2M | 236.5M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -46.0K | -826.0K | -481.0K | 2.14M | 793.0K | 1.58M | -21.5B | -14.8B | 55.5B | -31.7B |
| Capital spending | -97.0K | -224.0K | -237.0K | -1.75B | -1.72B | -1.32B | -1.79B | -1.40B | -1.46B | -1.71B |
| Free cash flow | -143.0K | -1.05M | -718.0K | 2.14B | 8.80B | -9.07B | -23.2B | -16.2B | 54.0B | -33.4B |
| Cash from investing | -97.0K | -224.0K | -424.0K | -21.7B | 4.27B | -18.4B | -24.0B | 1.25B | 3.50B | 36.7B |
| Cash from financing | -204.0K | 151.0K | -1.06M | -209.0K | -400.0K | -146.0K | 21.6B | 17.2B | 6.30B | 42.1B |
| Dividends paid | -2.19B | -1.93B | -1.36B | -936.0M | ||||||
| Share buybacks | -5.25B | -4.13B | -1.67B | -1.41B | -3.08B | -4.07B | -580.0M | -1.73B | ||
| Change in cash | -347.0K | -899.0K | -1.97M | 19.6B | 49.1B | 43.5B | -27.1B | -10.9B | 60.5B | 57.6B |
Cap table
Built by 6ix from Proteome Sciences plc’s releases · as of Jan 28, 2026
- Common shares
- 350,724,912
- Fully diluted
- 350,724,912
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 350,724,912 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 350,724,912 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Christopher Pearce | Executive Chairman · Since at least Sep 16, 2026 |
| Helen Spice | Non-executive Director · Since at least Sep 16, 2026 |
| Ian Pike | Board Member · Since at least May 14, 2026 |
| Martin Diggle | Board Member · Since at least Dec 23, 2024 |
| Richard Dennis | Chief Commercial Officer and Executive Director · Since at least Sep 16, 2026 |
Log in to ask 6ix AI your own questions about Proteome Sciences plc.